Andrés Muñoz Martín, Antonio Javier Trujillo-Santos, Edelmira Martí, Luis Jara-Palomares, Raquel Macías Montero, Enrique Gallardo, Juan José López-Núñez, Elena Brozos-Vázquez, Verónica Robles-Marinas, Pedro Pérez-Segura, Pedro Ruíz-Artacho
Cancer patients are at risk of venous thromboembolism (VTE), its recurrence, but also at risk of bleeding while anticoagulated. In addition, cancer therapies have been associated to increased VTE risk. Guidelines for VTE treatment in cancer patients recommend low molecular weight heparins (LMWH) or direct oral anticoagulants (DOAC) for the initial treatment, DOAC for VTE short-term treatment, and LMWH or DOAC for VTE long-term treatment. This consensus article arises from a collaboration between different Spanish experts on cancer-associated thrombosis...
February 13, 2024: Clinical & Translational Oncology